Literature DB >> 6624528

Tolerability of iohexol after injection into healthy volunteers.

K Levorstad, A Kolbenstvedt, F Kolmannskog, S C Sommerfelt, H Stormorken, E Andrew, K Sveen.   

Abstract

The effects of iohexol, a new non-ionic contrast medium, after intravenous injection into humans are reported. After injection of small doses into 2 subjects, iohexol was injected intravenously into 20 healthy male volunteers in doses of 125 to 500 mg I/kg body weight. A large number of physiologic, biochemical, hematologic and pharmacokinetic parameters were analysed. The results indicated that iohexol was well tolerated and that clinical trials in patients could be undertaken.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6624528     DOI: 10.1177/028418518302400311

Source DB:  PubMed          Journal:  Acta Radiol Diagn (Stockh)        ISSN: 0567-8056


  3 in total

1.  Contrast enhancement of brain tumors and irradiated normal brain: a comparison of iohexol and iothalamate.

Authors:  J R Fike; C E Cann; K Turowski; D Norman; L Ax
Journal:  Neuroradiology       Date:  1986       Impact factor: 2.804

2.  Comparison of iohexol 300 mg I/ml and Hexabrix 320 mg I/ml in central angiography. A double-blind trial.

Authors:  J Valk; F Crezée; R G Olislagers-de Slegte
Journal:  Neuroradiology       Date:  1984       Impact factor: 2.804

3.  The pharmacokinetic profile, tolerability and safety of the iodinated, non-ionic, dimeric contrast medium Iosimenol 340 injection in healthy human subjects.

Authors:  Karoline Meurer; Bettina Kelsch; Barry Hogstrom
Journal:  Acta Radiol       Date:  2014-06-03       Impact factor: 1.990

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.